在最新临床研究中,Aprea Therapeutics公司采用220毫克剂量治疗方案取得突破性进展。该剂量水平不仅实现肿瘤体积缩小达50%的显著效果,更令人瞩目的是观察到CA-125生物标志物水平的实质性下降。这一双重积极指标为卵巢癌等恶性肿瘤的靶向治疗开辟了新路径。
在最新临床研究中,Aprea Therapeutics公司采用220毫克剂量治疗方案取得突破性进展。该剂量水平不仅实现肿瘤体积缩小达50%的显著效果,更令人瞩目的是观察到CA-125生物标志物水平的实质性下降。这一双重积极指标为卵巢癌等恶性肿瘤的靶向治疗开辟了新路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.